$299 Million is the total value of Altium Capital Management LP's 118 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 275.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PTGX | New | PROTAGONIST THERAPEUTICS INCcall | $11,840,000 | – | 5,000 | +100.0% | 3.96% | – |
PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $9,140,000 | -22.8% | 386,000 | +11.6% | 3.06% | -6.3% |
New | PEPPERLIME HEALTH ACQUSTN COunit 99/99/9999 | $7,232,000 | – | 735,000 | +100.0% | 2.42% | – | |
KROS | Buy | KEROS THERAPEUTICS INC | $6,852,000 | +1.0% | 126,000 | +8.6% | 2.29% | +22.6% |
DXCM | New | DEXCOM INC | $6,395,000 | – | 12,500 | +100.0% | 2.14% | – |
INSM | Buy | INSMED INC | $6,298,000 | +13.7% | 268,000 | +31.8% | 2.11% | +38.0% |
QDEL | Buy | QUIDEL CORP | $6,298,000 | +26.1% | 56,000 | +51.4% | 2.11% | +53.1% |
GMED | Buy | GLOBUS MED INCcl a | $5,829,000 | +36.8% | 79,000 | +33.9% | 1.95% | +66.0% |
TNDM | New | TANDEM DIABETES CARE INC | $5,815,000 | – | 50,000 | +100.0% | 1.95% | – |
NVRO | Buy | NEVRO CORP | $5,569,000 | +63.6% | 77,000 | +83.3% | 1.86% | +98.5% |
GKOS | Buy | GLAUKOS CORP | $5,435,000 | +51.0% | 94,000 | +16.0% | 1.82% | +83.2% |
NVST | New | ENVISTA HOLDINGS CORPORATION | $5,115,000 | – | 105,000 | +100.0% | 1.71% | – |
SWAV | New | SHOCKWAVE MED INC | $4,769,000 | – | 23,000 | +100.0% | 1.60% | – |
KPTI | New | KARYOPHARM THERAPEUTICS INC | $4,754,000 | – | 645,000 | +100.0% | 1.59% | – |
RNA | Buy | AVIDITY BIOSCIENCES INC | $4,488,000 | -16.1% | 243,000 | +8.0% | 1.50% | +1.8% |
IMGN | New | IMMUNOGEN INC | $4,379,000 | – | 920,000 | +100.0% | 1.46% | – |
VSTM | Buy | VERASTEM INC | $4,161,000 | -9.9% | 2,951,000 | +31.0% | 1.39% | +9.3% |
LIVN | New | LIVANOVA PLC | $4,092,000 | – | 50,000 | +100.0% | 1.37% | – |
EIGR | Buy | EIGER BIOPHARMACEUTICALS INC | $3,652,000 | +169.5% | 440,000 | +68.6% | 1.22% | +226.7% |
KRTX | New | KARUNA THERAPEUTICS INC | $2,663,000 | – | 21,000 | +100.0% | 0.89% | – |
OM | New | OUTSET MED INC | $2,361,000 | – | 52,007 | +100.0% | 0.79% | – |
Buy | HILLMAN SOLUTIONS CORP | $2,328,000 | +52.5% | 196,000 | +38.0% | 0.78% | +85.0% | |
SLN | New | SILENCE THERAPEUTICS PLCads | $2,071,000 | – | 109,000 | +100.0% | 0.69% | – |
CARA | New | CARA THERAPEUTICS INC | $2,005,000 | – | 165,000 | +100.0% | 0.67% | – |
New | 2SEVENTY BIO INC | $1,962,000 | – | 115,000 | +100.0% | 0.66% | – | |
ALT | New | ALTIMMUNE INC | $1,961,000 | – | 322,000 | +100.0% | 0.66% | – |
AGIO | New | AGIOS PHARMACEUTICALS INC | $1,927,000 | – | 66,196 | +100.0% | 0.64% | – |
Buy | PARDES BIOSCIENCES INC | $1,827,000 | -44.2% | 253,000 | +26.5% | 0.61% | -32.3% | |
New | PROCEPT BIOROBOTICS CORP | $1,647,000 | – | 47,077 | +100.0% | 0.55% | – | |
New | AULT DISRUPTIVE TECHS CORP | $1,496,000 | – | 150,000 | +100.0% | 0.50% | – | |
New | SOMALOGIC INC | $1,444,000 | – | 180,000 | +100.0% | 0.48% | – | |
ITCI | New | INTRA-CELLULAR THERAPIES INC | $1,377,000 | – | 22,500 | +100.0% | 0.46% | – |
CUTR | New | CUTERA INC | $1,035,000 | – | 15,000 | +100.0% | 0.35% | – |
New | MURPHY CANYON ACQUISITION COunit 01/25/2027 | $1,010,000 | – | 100,000 | +100.0% | 0.34% | – | |
New | RELATIVITY ACQUISITION CORPunit 02/10/2027 | $1,007,000 | – | 100,000 | +100.0% | 0.34% | – | |
New | WESTERN ACQSTN VENTURES CORPunit 09/01/2026 | $1,000,000 | – | 100,000 | +100.0% | 0.34% | – | |
New | OPY ACQUISITION CORP I | $980,000 | – | 100,000 | +100.0% | 0.33% | – | |
New | GSR II METEORA ACQUISITN CORunit 02/24/2027 | $506,000 | – | 50,000 | +100.0% | 0.17% | – | |
New | TC BIOPHARM HOLDINGS PLC*w exp 02/08/202 | $461,000 | – | 941,176 | +100.0% | 0.15% | – | |
ZEVWS | New | LIGHTNING EMOTORS INC*w exp 05/18/202 | $268,000 | – | 652,173 | +100.0% | 0.09% | – |
New | CEA INDUSTRIES INC*w exp 02/11/202 | $171,000 | – | 250,000 | +100.0% | 0.06% | – | |
New | DIRECT DIGITAL HOLDINGS INC*w exp 02/15/202 | $131,000 | – | 180,000 | +100.0% | 0.04% | – | |
CALA | New | CALITHERA BIOSCIENCES INC | $82,000 | – | 202,276 | +100.0% | 0.03% | – |
New | OPY ACQUISITION CORP I*w exp 09/22/202 | $20,000 | – | 50,000 | +100.0% | 0.01% | – | |
New | AULT DISRUPTIVE TECHS CORP*w exp 99/99/999 | $19,000 | – | 112,500 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
FAT BRANDS INC | 12 | Q3 2023 | 0.6% |
CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.9% |
BELLUS HEALTH INC NEW | 10 | Q1 2023 | 4.7% |
XTANT MED HLDGS INC | 10 | Q3 2023 | 5.1% |
IVERIC BIO INC | 10 | Q1 2023 | 2.3% |
MYRIAD GENETICS INC | 10 | Q1 2023 | 2.3% |
HARBOR CUSTOM DEVELOPMENT IN | 10 | Q3 2023 | 0.1% |
CRINETICS PHARMACEUTICALS IN | 9 | Q3 2023 | 4.1% |
CTI BIOPHARMA CORP | 9 | Q1 2023 | 2.6% |
POLISHED COM INC | 9 | Q2 2023 | 3.4% |
View Altium Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Marpai, Inc. | April 26, 2023 | 1,805,327 | 6.2% |
Astria Therapeutics, Inc. | February 14, 2023 | 1,355,372 | 5.0% |
HyreCar Inc. | February 14, 2023 | 1,688,120 | 5.6% |
Muscle Maker, Inc. | February 14, 2023 | 2,888,085 | 5.0% |
NeuroBo Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
PALISADE BIO, INC.Sold out | February 14, 2023 | 0 | 0.0% |
1847 Goedeker Inc. | February 14, 2022 | 6,103,824 | 5.0% |
BioRestorative Therapies, Inc. | February 14, 2022 | 200,000 | 5.0% |
BriaCell Therapeutics Corp. | February 14, 2022 | 900,000 | 4.7% |
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | February 14, 2022 | 363,000 | 5.0% |
View Altium Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-02-21 |
SC 13G | 2024-02-20 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
View Altium Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.